Why is it you think institutions are pounding on the door? What is it CTSO is bringing to the table…i see a need for around 200 million on the low end between a FDA trial and up grading manufacturing. Are you saying institutions are willing wait out the growth period in the EU for a company with less than a million in sales? As for the R/s why is chan even talking about it? I saw in the company statement there would be no further dilution. How's that not possible without giving away massive equity in a deal.
Agree with all but the r/s if the company makes enough money the market will move the price w/o a r/s split. They nned to get that revenue stream kicking and provide more US related updates. I for one don't think the share structure is the biggest issue they have...
News 
Market Data 
Discover 
